XNCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Xencor Inc (XNCR) is not a strong buy for a beginner, long-term investor at this time. While the company's financials show revenue growth, the significant decline in net income and EPS, coupled with insider selling and lack of recent positive news catalysts, suggest caution. Analysts have raised price targets, but the stock's technical indicators and trading trends do not currently support a strong entry point.
The MACD is positive and expanding, indicating a potential upward trend, but RSI is neutral at 47.624, and moving averages are converging, showing no clear direction. The stock is trading close to its support level (S1: 11.179), with resistance at R1: 12.493.
Analysts have raised price targets recently, with some expressing optimism about the company's immunology and inflammation pipeline. Revenue increased by 18% YoY in Q3 2025.
Insiders are selling heavily, with a 2127.20% increase in selling over the last month. Net income and EPS have significantly declined YoY. No recent news or Congress trading data to support positive sentiment.
In Q3 2025, revenue increased by 18% YoY to $20.99M. However, net income dropped by 86.98% YoY to -$6.03M, and EPS fell by 88.89% YoY to -$0.08. Gross margin remained stable at 100%.
Analysts have raised price targets recently, with Barclays increasing it to $26 and Truist initiating coverage with a Buy rating and a $29 target. However, BofA maintains a Neutral rating, citing broader biotech market concerns.
